Will the price of adagrasib decrease in the future?

Adagrasib (Adagrasib) is a drug used to treat adult patients with advanced non-small cell lung cancer (NSCLC), when the cancer cells develop specific genetic changes (mutations) in KRAS G12C. It is used in patients whose condition has worsened after at least one systemic therapy (treatment that is given by injection or orally and affects the entire body). Genetic changes in the KRAS gene can produce altered forms of the KRAS protein, causing cancer cells to grow out of control. Adagrasib contains the active substance adagrasib, which attaches to altered proteins within cancer cells and prevents the proteins from functioning, thus slowing the growth and spread of cells. It also encourages the process of killing cancer cells.

The original drug of adagrasib is a drug that has not yet been marketed in China and therefore cannot be included in the scope of medical insurance. Patients can only purchase the drug through overseas channels. However, the original research version of adagrasib sold overseas is very expensive. Each box is 200mg*180 tablets and sells for about hundreds of thousands of yuan (the price may fluctuate due to exchange rates). As time changes, if other pharmaceutical companies develop and sell adagrasibu, its price will decrease.

According to the latest news, a generic drug of adagrasibu has been developed overseas and has begun sales. The ingredients of this generic drug are basically the same as the original drug. It is produced by Lucius Pharmaceutical Factory in Laos. Each box has a specification of 200mg*90 tablets and sells for about more than 4,000 yuan (the price may fluctuate due to exchange rates). Compared with the original drug, the price of the generic drug is more affordable and much cheaper. For more information on overseas drug prices and related information, please consult Yaode Medical Consultant.